Divi’s Laboratories Ltd. (DIVISLAB) Share Price Hits New 52-Week High
- July 31, 2026
- Posted by: Harsh Piplani
- Category: News
Divi’s Laboratories Ltd. Share Price hits a fresh 52-week high at Rs 8,086.55, rising 2.28% today with a market cap of Rs 2,06,906.21 crore.
Divi’s Laboratories Ltd. Share Price has reached a fresh 52-week high of Rs 8,086.55, marking a significant milestone for the company. The stock opened at Rs 7,841.5 and closed at Rs 8,018.9, reflecting a day change of Rs 178.4 or 2.28%. With a market capitalisation of Rs 2,06,906.21 crore, Divi’s Laboratories Ltd. continues to capture investor interest. This achievement highlights the company’s strong position within the healthcare sector, as it navigates market dynamics and competitive pressures.
Divi’s Laboratories Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 8,018.9 |
| Previous Close | Rs 7,840.5 |
| Today's Change | +Rs 178.4 (+2.28%) |
| Day Open | Rs 7,841.5 |
| Fresh 52-Week High | Rs 8,086.55 |
| Day Low | Rs 7,841.5 |
| Current Volume | 6,308 |
| Turnover | Rs 5.06 crore |
| Market Capitalisation | Rs 2,06,906.21 crore |
Divi's Laboratories Ltd. (DIVISLAB) traded at Rs 8,018.9. versus the previous close of Rs 7,840.5, a rise of 2.28%. The stock opened at Rs 7,841.5, reached Rs 8,086.55, touched Rs 7,841.5. Reported volume was 6,308.
Today, Divi’s Laboratories Ltd. Share Price opened at Rs 7,841.5, reaching a high of Rs 8,086.55 and a low of Rs 7,841.5. The stock closed at Rs 8,018.9, up by Rs 178.4 or 2.28% from the previous close of Rs 7,840.5. The turnover for the day was Rs 5.06 crore, with a volume of 6,308 shares traded. This fresh 52-week high indicates robust investor confidence and increased market participation, as the stock continues to perform well in the healthcare sector.
Divi's Laboratories Ltd. (DIVISLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,06,906.21 crore |
| P/E Ratio | 39.17x |
| P/B Ratio | 7.93x |
| ROE | 28.21% |
| ROCE | 26.35% |
Divi's Laboratories Ltd. was valued at a P/E ratio of 39.17x, a P/B ratio of 7.93x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 39.17x |
| Benchmark Median P/E | 20.13x |
| Benchmark Average P/E | 73.73x |
| Benchmark P/E Range | 0x to 3,417.8x |
| Company P/B Ratio | 7.93x |
| Benchmark Median P/B | 1.92x |
| Company ROE | 28.21% |
| Benchmark Median ROE | 10.73% |
| Company ROCE | 26.35% |
| Benchmark Median ROCE | 13.2% |
| Company Market Capitalisation | Rs 2,06,906.21 crore |
| Benchmark Median Market Cap | Rs 140.91 crore |
Divi's Laboratories Ltd. (DIVISLAB) is classified under sector: Healthcare.
Divi's Laboratories Ltd. (DIVISLAB) has a P/E ratio of 39.17x, which is above the benchmark median of 20.13x, a difference of +94.59%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Divi's Laboratories Ltd. (DIVISLAB) has a ROE of 28.21%, which is above the benchmark median of 10.73%, a difference of +162.91%. Divi's Laboratories Ltd. (DIVISLAB) has a ROCE of 26.35%, which is above the benchmark median of 13.2%, a difference of +99.62%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd. | KPL | 2,700.98 | 39.17 | 7.93 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,475.7 | 58.88 | 9.32 | 18.65 | 22.17 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,439.14 | 165.82 | 3.06 | 13.9 | 12.97 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,424.44 | 34.59 | 7 | -2.6 | 16.92 |
| Venus Remedies Ltd. | VENUSREM-BE | 2,150.28 | 17.79 | 3.01 | 9.85 | 7.89 |
Divi's Laboratories Ltd. (DIVISLAB) has a P/E ratio of 39.17x compared with the displayed peer median of 39.17x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Divi's Laboratories Ltd. (DIVISLAB) has a market capitalisation of Rs 2,06,906.21 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Divi’s Laboratories Ltd.
- Divi’s Laboratories Ltd. Share Price reached a fresh 52-week high, indicating strong market interest.
- The company exhibits solid financial fundamentals with high ROE and ROCE.
- Divi’s Laboratories Ltd. maintains a strong position within the healthcare sector.
- Peer comparison highlights its competitive edge in terms of profitability.
About Divi’s Laboratories Ltd.
Divi’s Laboratories Ltd. is a leading player in the healthcare sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company serves a global clientele, providing high-quality products that meet stringent regulatory standards. With a strong emphasis on research and development, Divi’s Laboratories Ltd. continues to innovate and expand its product portfolio, reinforcing its position as a trusted partner in the pharmaceutical industry.
Track Divi’s Laboratories Ltd. Share Price on Univest
Use Divi's Laboratories Ltd. (DIVISLAB) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Divi’s Laboratories Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay informed about the latest developments and make data-driven investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Divi's Laboratories Ltd.?
Ans. The current share price of Divi's Laboratories Ltd. is Rs 8,018.9, reflecting a 2.28% increase from the previous close. The stock moved 2.28% during the session. The intraday range extended from Rs 7,841.5 to Rs 8,086.55.
What is the 52-week high of Divi's Laboratories Ltd.?
Ans. Divi's Laboratories Ltd. has reached a fresh 52-week high of Rs 8,086.55, indicating strong market performance. The stock moved 2.28% during the session. The intraday range extended from Rs 7,841.5 to Rs 8,086.55.
How does Divi's Laboratories Ltd.'s P/E ratio compare to the sector?
Ans. Divi's Laboratories Ltd.'s P/E ratio of 39.17 is above the sector median of 20.13 but below the average of 73.73. The company trades at a P/E ratio of 39.17x. Its P/B ratio is 7.93x.
What is the market capitalisation of Divi's Laboratories Ltd.?
Ans. The market capitalisation of Divi's Laboratories Ltd. is Rs 2,06,906.21 crore, making it a major player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 39.17x.
What are the ROE and ROCE of Divi's Laboratories Ltd.?
Ans. Divi's Laboratories Ltd. has an ROE of 28.21% and a ROCE of 26.35%, indicating strong financial performance. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.73%.
How does Divi's Laboratories Ltd. compare to its peers?
Ans. Divi's Laboratories Ltd. shows a competitive edge with a P/E ratio of 39.17 and superior ROE and ROCE compared to many peers. Comparable listed companies include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Sai Parenteral's Ltd.
What is the P/B ratio of Divi's Laboratories Ltd.?
Ans. The P/B ratio of Divi's Laboratories Ltd. is 7.93, reflecting the company's valuation relative to its book value. The company trades at a P/E ratio of 39.17x. Its P/B ratio is 7.93x.
Investor Insights and Market Trends
Investors are closely monitoring Divi’s Laboratories Ltd. due to its robust performance and strategic positioning within the healthcare sector. The company’s ability to consistently achieve high returns on equity and capital employed demonstrates its operational efficiency and effective management strategies. As the healthcare industry continues to evolve, Divi’s Laboratories Ltd. is well-positioned to capitalize on emerging trends and opportunities, further solidifying its market presence.
The healthcare sector is experiencing significant growth driven by increasing demand for pharmaceutical products and healthcare services. Divi’s Laboratories Ltd., with its strong focus on research and development, is poised to benefit from this trend. The company’s commitment to innovation and quality ensures that it remains a preferred partner for global pharmaceutical companies, enhancing its competitive advantage.
Market analysts are optimistic about the future prospects of Divi’s Laboratories Ltd., citing its strong financial performance and strategic initiatives as key drivers of growth. The company’s ability to adapt to changing market conditions and leverage its expertise in the pharmaceutical industry positions it for sustained success.
Investors seeking exposure to the healthcare sector may find Divi’s Laboratories Ltd. an attractive option due to its solid fundamentals and growth potential. The company’s track record of delivering consistent returns and its strategic focus on expanding its product portfolio make it a compelling investment opportunity.
As Divi’s Laboratories Ltd. continues to achieve new milestones, investors are encouraged to stay informed about the latest developments and market trends. By leveraging data-driven insights and analysis, investors can make informed decisions and capitalize on the opportunities presented by this leading healthcare company.
